Biopharmaceutical company Oakrum Pharma LLC revealed on Monday the launch of an agreement to develop and manufacture two prescription generic pharmaceutical products to be commercialised in the US under the Oakrum label.
The company said it has signed the product development and commercialisation partnership with Biophore India Pharmaceuticals Pvt Ltd, a pharmaceutical company.
Both the prescription generic pharmaceutical products are expected to be sold through the specialty distribution market channel.
For the 12-month period ending 31 December 2018, the total market for the products in the US exceeded USD150m in aggregate sales, according to Bloomberg data.
Amerigen wins US FDA approval for generic Penicillamine in 250 mg capsules
Amerigen Pharmaceuticals Limited wins US FDA approval for Penicillamine Capsules USP in 250 mg
Dr. Reddy's Laboratories Launches Testosterone Gel, 1.62% in the US Market
Teva Provides Update on Fremanezumab Clinical Development for Use in Episodic Cluster Headache
Teva Launches Generic Version of VESIcare Tablets in the United States
Teva Pharmaceutical begins US launch of generic VESIcare tablets
Oakrum Pharma signs product development and commercialisation partnership with Biophore
Teva Pharmaceutical launches generic version of VESIcare tablets in the US
Phyton Biotech and AqVida receive European approval for paclitaxel injectable FDF
The United States Food and Drug Administration approves Narcan
Teva Signs New USD 2.3bn Syndicated Revolving Credit Facility
Endo announces delivery of authorised generic PROVENTIL (albuterol sulfate) in the US